lncRNA PVT1 in the Pathogenesis and Clinical Management of
Renal Cell Carcinoma

J 2021

lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ a Ondřej SLABÝ

Základní údaje

Originální název

lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

Autoři

BOHOŠOVÁ, Júlia (703 Slovensko, domácí), Adéla KUBÍČKOVÁ (203 Česká republika, domácí) a Ondřej SLABÝ (203 Česká republika, garant, domácí)

Vydání

Biomolecules, BASEL, MDPI, 2021, 2218-273X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.064

Kód RIV

RIV/00216224:14110/21:00120232

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/biom11050664

UT WoS

000653480900001

Klíčová slova anglicky

biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis

Štítky

14110513, 14110516, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 2. 2022 07:28, Mgr. Tereza Miškechová

Anotace

V originále

LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.

Návaznosti

NV18-03-00554, projekt VaV

Název: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministerstvo zdravotnictví ČR, Molecular classification of renal cell carcinoma based on long noncoding RNAs expression and its implication for diagnosis, prognosis and therapy

Citovat

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ a Ondřej SLABÝ. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. Biomolecules. BASEL: MDPI, 2021, roč. 11, č. 5, s. 1-12. ISSN 2218-273X. Dostupné z: https://dx.doi.org/10.3390/biom11050664.

@article{1836841,
   author = {Bohošová, Júlia and Kubíčková, Adéla and Slabý, Ondřej},
   article_location = {BASEL},
   article_number = {5},
   doi = {http://dx.doi.org/10.3390/biom11050664},
   keywords = {biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis},
   language = {eng},
   issn = {2218-273X},
   journal = {Biomolecules},
   title = {lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma},
   url = {https://www.mdpi.com/2218-273X/11/5/664},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1836841
AU  - Bohošová, Júlia - Kubíčková, Adéla - Slabý, Ondřej
PY  - 2021
TI  - lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
JF  - Biomolecules
VL  - 11
IS  - 5
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 2218273X
KW  - biomarker
KW  - prognosis
KW  - diagnosis
KW  - long non-coding RNA
KW  - tumorigenesis
UR  - https://www.mdpi.com/2218-273X/11/5/664
N2  - LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.
ER  -

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ a Ondřej SLABÝ. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. \textit{Biomolecules}. BASEL: MDPI, 2021, roč.~11, č.~5, s.~1-12. ISSN~2218-273X. Dostupné z: https://dx.doi.org/10.3390/biom11050664.

Podrobný výpis o publikaci